However, potential influences of these non-imprinted genes on drug response cannot be excluded, as expression of ZNF217 was weakly associated with response to lenalidomide in the Beat AML dataset (ρ = 0.261, pFDR = 0.065; Additional file 11: Table S8, Additional file 12: Fig. S4). The gene discussed is ZNF217; the disease is acute myeloid leukemia.